BREXIDOL ® Piroxicam

BREXIDOL ® is a Piroxicam based drug

THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions BREXIDOL ® Piroxicam

BREXIDOL ® is indicated in the treatment of inflammatory joint pain present in rheumatic and traumatic diseases.

Mechanism of action BREXIDOL ® Piroxicam

BREXIDOL ® is a medicine based on Piroxicam, an active ingredient belonging to the category of non-steroidal anti-inflammatory drugs and the forefather of the class of oxicam, able to guarantee topical absorption of the drug.

In fact, pharmacokinetic studies show that the application of medicated plasters can reduce the systemic absorption of Piroxicam compared to the oral drug, allowing instead its accumulation mainly in the synovial area, and thus ensuring a therapeutic action concentrated at the joint level.

The pain-relieving properties of Piroxicam are essentially due to the ability of this active principle to selectively inhibit cyclooxygenases 2, enzymes activated by inflammatory stimuli and involved in the synthesis of chemical mediators, known as prostaglandins, with pro-inflammatory and algogenic activity.

Recent studies have also attributed to this active ingredient also a significant antioxidant and histoprotective action, linked to the ability to detoxify the tissue from hydrogen peroxide, thus protecting it both from oxidative damage induced by reactive oxygen species and from damage induced by enzymes with overexpressed proteolytic activity during inflammatory processes.

In addition to a therapeutic action concentrated mainly at the local level, the topical application of Piroxicam also significantly reduces the side effects associated with oral therapy, and in particular those at the gastro-intestinal level, thus ensuring greater tolerability.

Studies carried out and clinical efficacy

1. PIROXICAM PATTERNS IN THE POST-ERPETIC NEVRALGIA

Ann Dermatol. 2011 May; 23 (2): 162-9. Epub 2011 May 27.

Interesting work that shows how the use of Piroxicam medicated plasters can be more effective and above all safe compared to lidocaine patches, in the treatment of neuropathic pain such as post-herpetic neuralgia.

2. THE EXCELLENT COMPLIANCE OF PATTERNS MEDICATED TO PIROXICAM IN PATIENTS WITH OSTEOARTRITIS

Arzneimittelforschung. 2009; 59 (8): 403-9.

Study conducted on numerous patients suffering from osteoarthritis who demonstrated how the application of Piroxicam patches can be more effective and above all better accepted by patients than the use of creams. The best compliance is essentially due to the possibility of applying the patch once a day and not three times as in the case of creams.

3. MULTIFORM ERITEMA INDUCED BY PIROXICAM

Contact Dermatitis. 2004 Apr; 50 (4): 263.

Case report reporting the appearance of erythema multiforme following the topical application of Piroxicam. These studies emphasize the importance of contacting your doctor before taking this medicine.

Method of use and dosage

BREXIDOL ®

Piroxicam 14 mg medicated plasters.

For the symptomatic treatment of painful articular states, both on a rheumatic and traumatic basis, it is recommended to apply a patch per day to intact skin at the painful joint.

Therapy should not exceed 8 days.

In any case, it is recommended to consult your doctor before starting BREXIDOL ® therapy

Warnings BREXIDOL ® Piroxicam

Although BREXIDOL ® appears to be a drug that is not subject to mandatory medical prescription, and therefore freely salable, it would be advisable to consult your doctor before starting treatment with this drug.

Before applying the patch it would be advisable to clean the skin region and ascertain the absence of skin lesions or inflammation.

Repeated and prolonged use over time could expose the treated area to dermatological allergic reactions.

It is also recommended to avoid exposure of the treated area to sunlight, given the photosensitizing capacity of Piroxicam.

Patients suffering from hepatic, renal, coagulative and gastro-enteric diseases should pay particular attention to taking BREXIDOL ® and consult your doctor.

PREGNANCY AND BREASTFEEDING

Despite the systemic absorption of Piroxicam during BREXIDOL ® therapy is insignificant, the absence of clinical trials able to assess the safety of this drug on the unborn child, when taken during pregnancy, oblige us to extend the contraindications to use also to pregnancy and the subsequent breastfeeding period.

Interactions

The topical application of Piroxicam allows the risk of potential drug interactions with other active ingredients capable of varying both the efficacy of action and the safety profile to be reduced to the point of elimination.

Contraindications BREXIDOL ® Piroxicam

The use of BREXIDOL ® is contraindicated in case of hypersensitivity to the active ingredient, to one of its excipients or to other NSAIDs, contextual use of anticoagulants or other non-steroidal anti-inflammatory drugs.

It is recommended not to apply BREXIDOL ® on damaged or inflamed skin.

Undesirable effects - Side effects

The topical application of Piroxicam and the consequent low systemic absorption allow to significantly reduce the risk of adverse reactions generally associated with the oral intake of the drug.

However, it is important to remember that the use of BREXIDOL ® can determine, in the area where the patch is applied, the appearance of erythema, itching, burning, contact dermatitis and other dermatological reactions.

Given the photo-sensitizing properties of Piroxicam, it is advisable to avoid sun exposure throughout the therapy.